** Drug developer Neumora Therapeutics' shares fall 82% to $1.95
** NMRA says its experimental depression drug, navacaprant, did not meet the main goal in a late-stage trial
** The drug did not reduce symptoms of depression as measured on a disease severity scale that tracks sadness, reduced sleep and pessimistic thoughts
** NMRA says the drug also did not show statistically significant improvement on a key secondary goal
** Co says its cash balance of $342 mln at the end of the Q3 will fund operations into mid-2026
** NMRA declined ~38% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。